Company News & Events

Roche and Oryzon announce collaboration to develop epigenetics-based medicines

7 April 2014

Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions

Lead agent ORY-1001 currently in phase I/IIa study in AML

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Oryzon Genomics SA today announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethylase-1 (LSD1; KDM1A), an epigenetic modulator that regulates gene expression.

Click here to see the full Press Release.

Share this story